Giovanni Martinelli

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. doi request reprint Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
  2. pmc Imputation reliability on DNA biallelic markers for drug metabolism studies
    Vladan Mijatovic
    Dep, of Life and Reproductions Sciences, Sec, of Biology and Genetics University of Verona, Strada Le Grazie 8, 37134 Verona, Italy
    BMC Bioinformatics 13:S7. 2012
  3. doi request reprint IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report
    Giovanni Martinelli
    Molecular Biology Unit, Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    J Clin Oncol 27:5202-7. 2009
  4. doi request reprint New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 2:297-303. 2009
  5. ncbi request reprint Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy
    Clin Adv Hematol Oncol 6:303-10. 2008
  6. doi request reprint Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients
    I Iacobucci
    Department of Institute of Hematology and Medical Oncology, L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna 9 40138, Italy
    Leukemia 24:66-73. 2010
  7. doi request reprint New targets for Ph+ leukaemia therapy
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Best Pract Res Clin Haematol 22:445-54. 2009
  8. ncbi request reprint ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
  9. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
  10. ncbi request reprint Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006

Detail Information

Publications103 found, 100 shown here

  1. doi request reprint Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
    ..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...
  2. pmc Imputation reliability on DNA biallelic markers for drug metabolism studies
    Vladan Mijatovic
    Dep, of Life and Reproductions Sciences, Sec, of Biology and Genetics University of Verona, Strada Le Grazie 8, 37134 Verona, Italy
    BMC Bioinformatics 13:S7. 2012
    ....
  3. doi request reprint IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report
    Giovanni Martinelli
    Molecular Biology Unit, Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    J Clin Oncol 27:5202-7. 2009
    ....
  4. doi request reprint New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 2:297-303. 2009
    ..New therapeutic approaches are now available, such as dasatinib, nilotinib and bosutinib, and we highlight those that may be applicable to the treatment of adult BCR-ABL1-positive ALL...
  5. ncbi request reprint Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy
    Clin Adv Hematol Oncol 6:303-10. 2008
    ..Early results from studies combining tipifarnib with imatinib or etoposide in CML and AML have been promising and warrant further evaluation in larger clinical trials...
  6. doi request reprint Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients
    I Iacobucci
    Department of Institute of Hematology and Medical Oncology, L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna 9 40138, Italy
    Leukemia 24:66-73. 2010
    ..In conclusion, BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability...
  7. doi request reprint New targets for Ph+ leukaemia therapy
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Best Pract Res Clin Haematol 22:445-54. 2009
    ..In this review, we highlight the most promising drugs for the treatment of adult BCR-ABL-positive leukaemias...
  8. ncbi request reprint ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
    ....
  9. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  10. ncbi request reprint Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..CCgR is durable in the majority of patients but relapse occurs in a subset...
  11. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  12. ncbi request reprint Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Hematol Oncol 24:196-204. 2006
    ..We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors...
  13. doi request reprint mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
    Manuela Mancini
    Dipartimento di Ematologia e Scienze Oncologiche Lorenzo e Ariosto Seràgnoli, University of Bologna, Italy
    Leuk Res 34:641-8. 2010
    ....
  14. doi request reprint Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
    ..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient...
  15. doi request reprint RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia
    Manuela Mancini
    Dipartimento di Ematologia e Scienze Oncologiche Lorenzo e Ariosto Seràgnoli, University of Bologna Medical School, Bologna, Italy
    J Cell Biochem 109:320-8. 2010
    ..RAD 001 cytotoxicity on cells not expressing the BCR-ABL fusion gene or its p210 protein tyrosine kinase (TK) activity suggests that the inhibition of normal hematopoiesis may represent a drug side effect...
  16. ncbi request reprint Imatinib mesylate in the treatment of hematologic malignancies
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
    Expert Opin Biol Ther 7:1597-611. 2007
    ..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases...
  17. ncbi request reprint Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012
    ..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy...
  18. doi request reprint Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leuke
    Ilaria Iacobucci
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 114:2159-67. 2009
    ....
  19. doi request reprint Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    Simona Soverini
    Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 114:2168-71. 2009
    ....
  20. doi request reprint Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
    Fausto Castagnetti
    Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 113:3428-34. 2009
    ..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926...
  21. ncbi request reprint Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:454-9. 2006
    ..Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia...
  22. ncbi request reprint Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Chem 50:1205-13. 2004
    ..Point mutations within the ABL kinase domain are emerging as the most frequent mechanism for reactivation of kinase activity within the leukemic clone...
  23. doi request reprint Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
    Giulia Marzocchi
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 117:6793-800. 2011
    ..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  24. pmc The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 95:1415-9. 2010
    ..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...
  25. ncbi request reprint Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
    ..ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients...
  26. ncbi request reprint Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Blood 104:4245-51. 2004
    ..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies...
  27. ncbi request reprint Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    Blood 102:1588-94. 2003
    ..055). We concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation...
  28. ncbi request reprint Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571
    Lucia Mazzacurati
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, University of Bologna, Medical School, Bologna, Italy
    Hematol J 5:168-77. 2004
    ..In CML, they might further enhance the proliferative advantage and genomic instability of clonal myeloid progenitors featuring a class of poor prognosis patients eventually resistant to STI571...
  29. ncbi request reprint First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Res 28:987-90. 2004
    ..Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients...
  30. doi request reprint Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Blood 114:5191-200. 2009
    ..Moreover, leukemic CD34(-) cells survived exposure to BCR-ABL inhibitors in vivo. Thus, we identified a novel CD34(-) leukemic stem cell subset in CML with peculiar molecular and functional characteristics...
  31. doi request reprint Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
    Francesca Palandri
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 93:1792-6. 2008
    ..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients...
  32. ncbi request reprint Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
    Simona Soverini
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Italy
    Lancet Oncol 8:273-4. 2007
  33. doi request reprint Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Clin Cancer Res 15:1059-63. 2009
    ..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib...
  34. ncbi request reprint Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 88:1221-8. 2003
    ..Other genes that have been implicated at the rearrangement breakpoint are GR6 and RPN1 (both on 3q21). The aim of this study was to investigate the expression of the EVI1 fusion genes in AML patients with 3q21q26 syndrome...
  35. ncbi request reprint Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer 110:1178-86. 2007
    ..It also has demonstrated promising efficacy in Ph+ ALL but is still being evaluated in phase 2 trials. In this article, the authors reviewed current knowledge on novel tyrosine-kinase inhibitors in adult Ph+ ALL patients...
  36. ncbi request reprint Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology L and A Serànoli, University of Bologna, Italy
    Blood 103:2284-90. 2004
    ..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet...
  37. pmc IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia
    Ilaria Iacobucci
    Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    PLoS ONE 7:e40934. 2012
    ....
  38. ncbi request reprint Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission
    Michele Malagola
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 89:ECR25. 2004
  39. doi request reprint Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia
    Matilde Y Follo
    Department of Human Anatomical Sciences, Cellular Signalling Laboratory, University of Bologna, Bologna, Italy
    J Clin Oncol 27:782-90. 2009
    ..To evaluate the association between the presence of phosphoinositide-phospholipase C beta1 (PI-PLCbeta1) mono-allelic deletion with the clinical outcome of myelodysplastic syndromes (MDS) patients...
  40. pmc Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Francesca Palandri
    Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:1758-61. 2009
    ..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited...
  41. pmc Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Simona Soverini
    Department of Haematology Oncology, L e A Serígnoli, University of Bologna, Bologna, Italy
    Oncologist 16:868-76. 2011
    ..Here, we discuss the pros and cons of using this approach in TKI selection...
  42. doi request reprint Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
    ..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance...
  43. doi request reprint Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
    Gabriele Gugliotta
    Department of Hematology and Oncology Seràgnoli, University of Bologna S Orsola Malpighi Hospital, Bologna, Italy
    Blood 117:5591-9. 2011
    ..These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www.clinicaltrials.gov as #NCT00514488 and #NCT00510926...
  44. doi request reprint Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Simona Soverini
    Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Leuk Res 35:1527-9. 2011
    ..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse...
  45. ncbi request reprint The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Haematologica 92:1173-9. 2007
    ..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate...
  46. doi request reprint Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Gianantonio Rosti
    Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
    Leuk Lymphoma 51:583-91. 2010
    ..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria...
  47. ncbi request reprint New tyrosine kinase inhibitors in chronic myeloid leukemia
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 90:534-41. 2005
    ..This review highlights the development of new TKI as specific molecularly targeted therapy and as the principal mechanisms for overcoming imatinib resistance...
  48. doi request reprint Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 113:4497-504. 2009
    ..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488...
  49. doi request reprint PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation
    William L Blalock
    Cell Signalling Laboratory, Department of Human Anatomical Sciences, University of Bologna, Bologna, Italy
    J Cell Physiol 221:232-41. 2009
    ....
  50. ncbi request reprint Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  51. doi request reprint Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia
    Michela Palmisano
    Institute of Hematology and Medical Oncology L e A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Hematology 13:1-12. 2008
    ....
  52. ncbi request reprint Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC
    Michele Bianchini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti no 9, 40138 Bologna, Italy
    Clin Chem 49:1642-50. 2003
    ....
  53. ncbi request reprint Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:101-5. 2007
    ..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients...
  54. ncbi request reprint Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606
    Manuela Mancini
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, University of Bologna Medical School, Via Massarenti 9, 40138 Bologna, Italy
    Leuk Res 31:979-87. 2007
    ..The putative roles of growth factor (namely IL-3) autocrine loop in BCR-ABL-expressing progenitor progression towards a drug-resistant phenotype are discussed...
  55. ncbi request reprint Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Lymphoma 45:731-3. 2004
    ..In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL...
  56. ncbi request reprint Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
    ....
  57. doi request reprint CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients
    Ilaria Iacobucci
    Department of Hematology and Oncological Sciences L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Italy
    Clin Cancer Res 17:7413-23. 2011
    ..The 9p21 locus, encoding three important tumor suppressors (p16/CDKN2A, p14/ARF, and p15/CDKN2B), is a major target of inactivation in the pathogenesis of many human tumors...
  58. ncbi request reprint Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR37. 2003
  59. ncbi request reprint Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 89:236-7. 2004
  60. pmc The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party
    Ilaria Iacobucci
    Molecular Biology Unit, Department of Hematology Oncology Seràgnoli, University of Bologna, Via Massarenti 9, Bologna, Italy
    Haematologica 95:1683-90. 2010
    ..So far the occurrence of PAX5 alterations and their clinical correlation have not been investigated in adults with BCR-ABL1-positive acute lymphoblastic leukemia...
  61. pmc Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
    Matilde Y Follo
    Cellular Signalling Laboratory, Department of Human Anatomical Sciences, University of Bologna, Via Irnerio 48, Bologna, Italy
    Proc Natl Acad Sci U S A 106:16811-6. 2009
    ....
  62. pmc The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:205-12. 2009
    ..The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available...
  63. ncbi request reprint Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  64. ncbi request reprint Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Silvia Buonamici
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Blood 99:443-9. 2002
    ..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML...
  65. pmc Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
    Simona Soverini
    Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 96:552-7. 2011
    ..We aimed to assess: (i) in how many patients BCR-ABL kinase domain mutations are already detectable at relatively low levels at the time of diagnosis, and (ii) whether mutation detection correlates with subsequent response to therapy...
  66. doi request reprint Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
    Nicoletta Testoni
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna and S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 114:4939-43. 2009
    ..I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  67. ncbi request reprint The cytogenetic response as a surrogate marker of survival
    Gianantonio Rosti
    Institute of Hematology and Clinical Oncology Seràgnoli Bologna University, Bologna, Italy
    Semin Hematol 40:56-61. 2003
    ..Low-risk patients survive longer than non-low-risk patients given the same CgR. Preliminary results from studies with imatinib are superior and CgR remains an important surrogate marker of survival in the imatinib era...
  68. doi request reprint c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells
    Antonio Porro
    Department of Biology, University of Bologna, Bologna, Italy
    Mol Cancer Res 9:1054-66. 2011
    ....
  69. ncbi request reprint Advances in the treatment for haematological malignancies
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    Expert Opin Pharmacother 7:721-32. 2006
    ..Although these novel therapies are beginning to fulfil their promise, continued research efforts are needed to determine the optimal role of these strategies in haemato-oncology...
  70. ncbi request reprint Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Opin Biol Ther 6:1011-22. 2006
    ..In addition, preliminary experiences with novel tyrosine kinase inhibitors in imatinib-resistant Ph+ ALL are discussed...
  71. ncbi request reprint Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR28. 2003
  72. ncbi request reprint Novel FLT3 point mutation in acute myeloid leukaemia
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, Italy
    Lancet Oncol 4:604. 2003
  73. ncbi request reprint Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Gianantonio Rosti
    L and A Seràgnoli Institute of Hematology and Medical Oncology, St Orsola Malpighi Hospital, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 88:256-9. 2003
    ....
  74. doi request reprint Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    Gianantonio Rosti
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
    Blood 114:4933-8. 2009
    ..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052...
  75. ncbi request reprint A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
    Michele Baccarani
    L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
    Blood 99:1527-35. 2002
    ....
  76. ncbi request reprint Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocation
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Haematologica 87:EIM08. 2002
  77. ncbi request reprint Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:688-94; discussion 694. 2002
    ..We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others...
  78. doi request reprint Imatinib mesylate for the treatment of chronic myeloid leukemia
    Simona Soverini
    Department of Hematology and Oncological Sciences Lorenzo e Ariosto Seràgnoli University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Expert Rev Anticancer Ther 8:853-64. 2008
    ..Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients...
  79. ncbi request reprint Interferon-alfa for chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna and S Orsola Hospital, Bologna, Italy
    Semin Hematol 40:22-33. 2003
    ....
  80. ncbi request reprint Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
    Michele Malagola
    Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Br J Haematol 136:87-95. 2007
    ..In this setting of patients, large prospective randomised studies should be planned...
  81. ncbi request reprint Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
    Franck Morschhauser
    Department of Hematology, Centre Hospitalier Universitaire, Lille, France
    Blood 110:54-8. 2007
    ..Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing...
  82. ncbi request reprint Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings
    Giovanni Martinelli
    Haematologica 87:554-5. 2002
  83. ncbi request reprint Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease
    Giuseppe Visani
    Haematologica 88:ELT15. 2003
  84. ncbi request reprint Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
    Simona Soverini
    Haematologica 92:437-9. 2007
  85. ncbi request reprint FLT3 inhibition as tailored therapy for acute myeloid leukemia
    Giovanni Martinelli
    Haematologica 88:4-8. 2003
  86. ncbi request reprint Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
    Oliver Ottmann
    Medizinische Klinik II, Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Blood 110:2309-15. 2007
    ..Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015...
  87. pmc Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    Timothy Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 108:28-37. 2006
    ..We recognize that our recommendations are provisional and will require revision as new evidence emerges...
  88. ncbi request reprint Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adu
    Marco Vignetti
    Department of Cellular Biotechnologies and Hematology, La Sapienza University, Via Benevento 6, 00161 Rome, Italy
    Blood 109:3676-8. 2007
    ....
  89. ncbi request reprint May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?
    Leonardo Potenza
    Leuk Res 31:269-71. 2007
  90. ncbi request reprint First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy
    Serena Merante
    J Clin Oncol 24:e6-7. 2006
  91. ncbi request reprint Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95
    Russell L Basser
    CSL Ltd, 45 Poplar Rd, Parkville, VIC 3052, Australia
    J Clin Oncol 24:370-8. 2006
    ....
  92. ncbi request reprint Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
    Simona Soverini
    J Clin Oncol 24:e51-2. 2006
  93. ncbi request reprint NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia
    Michela Palmisano
    Haematologica 92:1268-9. 2007
    ..They are associated with a wide spectrum of morphologic subtypes of AML, normal karyotype and FLT3 mutations. The high frequency of NPM1 mutations might provide a suitable marker for monitoring residual disease of AML...
  94. ncbi request reprint Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Domenico Russo
    Unit of Blood Diseases and Cell Therapy, Brescia University, Brescia, Italy
    Br J Haematol 131:172-9. 2005
    ..Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients...
  95. ncbi request reprint Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway
    Roberta Bortul
    Dipartimento di Morfologia Umana Normale, Universita di Trieste, Trieste, Italy
    Br J Haematol 129:677-86. 2005
    ..Overall, our results indicate that deguelin might be used in the future for increasing sensitivity to therapeutic treatments of leukaemia cells with an active PI3K/Akt signalling network...
  96. ncbi request reprint Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
    Michele Malagola
    Blood 105:904; author reply 905. 2005
  97. ncbi request reprint The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients
    Pier Paolo Piccaluga
    Haematologica 89:1269-71. 2004
    ..000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio <2 after 4 weeks of treatment had significantly better RFS (10.5 vs 4 months) (p=0.004)...
  98. ncbi request reprint No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
    Giuseppe Visani
    Department of Hematology, H San Salvatore, Pesaro, Italy
    Leuk Lymphoma 45:1361-4. 2004
    ....
  99. ncbi request reprint PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment
    Ernesto Vigna
    Unità Operativa di Ematologia Medicine, Cosenza, Italy
    Cancer Chemother Pharmacol 61:713-6. 2008
    ..We herein report a case of F/P-positive CEL with retro-orbital localization, who was successfully treated with imatinib...
  100. ncbi request reprint Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia
    Pier Paolo Piccaluga
    Eur J Haematol 72:302-3. 2004
  101. ncbi request reprint Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat
    Daniele Laszlo
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Eur J Haematol 72:264-7. 2004
    ....